Circulating tumor cell

Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Retrieved on: 
Thursday, October 7, 2021
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, NASDAQ, Private Securities Litigation Reform Act, Tumor microenvironment, IHC, Cancer, Circulating tumor cell, Clovis Oncology, Conference, Drug discovery, Poster, Antibody, Cell, Database administrator, Safety, FAP, Population, Sarcoma, FDA, Peptide, Gallium, U.S. Securities and Exchange Commission, Radiation, Immunohistochemistry, Autoradiograph, EMA, Security (finance), AACR, TRT, Mesothelioma, Therapy, Patient, Clinical trial, Isotope, Neoplasm, Research, View, Colon, Pharmaceutical industry, Medical imaging, FAP-2286, Targeted Radionuclide Therapy, the LuMIERE Clinical Study, Clovis Oncology, FAP-2286, TARGETED RADIONUCLIDE THERAPY, THE LUMIERE CLINICAL STUDY, CLOVIS ONCOLOGY

This is representative of our commitment to emerge as a leader in targeted radionuclide therapy by developing innovative radiotherapies such as FAP-2286 for patients with hard-to-treat cancers.

Key Points: 
  • This is representative of our commitment to emerge as a leader in targeted radionuclide therapy by developing innovative radiotherapies such as FAP-2286 for patients with hard-to-treat cancers.
  • To determine FAP protein expression in different tumor types, a pan-tumor IHC screen was performed that included 360 samples representing 16 different tumor types.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).
  • LuMIERE is a Phase 1/2 study evaluating FAP-2286 as a peptide-targeted radionuclide therapy (PTRT) targeting fibroblast activation protein, or FAP, in patients with advanced solid tumors (NCT04939610) .

Global Circulating Tumor Cell (CTC) Diagnostics Market Report 2021: Market to Reach $19 Billion by 2027 - CTC Microdevices Hog the Limelight - ResearchAndMarkets.com

Retrieved on: 
Monday, August 16, 2021
Research, Surgery, Medical Devices, Clinical Trials, Stem Cells, Biotechnology, Health, Science, Oncology, Diagnosis, Circulating tumor cell, CAGR, COVID-19, Growth, CTC, Pet, Renewable energy, Video game

The "Circulating Tumor Cell (CTC) Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Circulating Tumor Cell (CTC) Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$19 Billion by 2027, growing at a CAGR of 17.3% over the analysis period 2020-2027.
  • CTC Enrichment Methods, one of the segments analyzed in the report, is projected to record a 17.8% CAGR and reach US$9.6 Billion by the end of the analysis period.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.3 Billion by the year 2027.

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Professional services, White House, Federal Government, Health, Oncology, Other Science, Infectious diseases, Genetics, Public policy, Government, Insurance, Science, Clinical medicine, Medicine, Branches of biology, Oncology, HER2/neu, Circulating tumor cell, Breast cancer, Molecular diagnostics, Biomarker, MammaPrint, Breast cancer classification

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, has received a positive final Local Coverage Determination (LCD) that expands Medicare coverage for use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs).

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, has received a positive final Local Coverage Determination (LCD) that expands Medicare coverage for use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs).
  • This coverage determination from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program (MolDx) was effective July 4, 2021.
  • Given the efficacy of various anti-HER2 therapies, testing for HER2 is one of the most important sources of information used by oncologists in making treatment decisions for patients with breast cancer.
  • As a result, guidelines for breast cancer recommend that all patients with new primary or newly metastatic breast cancer be tested for HER2.

Nucleix Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients

Retrieved on: 
Thursday, June 3, 2021
Oncology, Health, Other Health, Research, Science, Biotechnology, Medicine, Clinical medicine, Biopsy, Interventional radiology, Liquid biopsy, Lung cancer, Assay, Circulating tumor cell, EpiCheck®, Nucleix, EPICHECK®, NUCLEIX

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleixs highly sensitive EpiCheck platform.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleixs highly sensitive EpiCheck platform.
  • The collaboration will focus initially on evaluating methylation markers believed to be important for the characterization of lung cancer subtypes.
  • For those markers that demonstrate efficacy in helping with this characterization, Nucleix will lead the development of new assays.
  • MD Anderson will work to validate assays using in vitro and in vivo cell lines, preclinical models and clinical samples.

$26.45 Billion Circulating Tumor Cells Market by Technology; Application; Product; Specimen - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, Oncology, Medicine, Clinical medicine, Medical specialties, Oncology, Anatomical pathology, Cancer pathology, Cancer, Metástasis, Liquid biopsy, Circulating tumor cell, Biopsy, Melanoma

Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.\nIn the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens.

Key Points: 
  • Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.\nIn the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens.
  • Currently, circulating tumor cell-based screening and analysis are at a nascent market stage.
  • The market dominance of cell-free DNA units over circulating tumor cells in cancer diagnosis has led to less share in clinical applications.
  • This high market growth is due to the fact that most of the products currently being on the market are primarily designed for research settings.

ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Transcription factors, Biology, PDAC, Pancreatic cancer, KRAS, SMAD, Mothers against decapentaplegic homolog 4, Anatomical pathology, Oncology, Circulating tumor cell

A peer-reviewed article, published in the journal Cancer Letters ( click to access article ), describes a Johns Hopkins Medicine study that validated PDAC CTC detection by a targeted scNGS method of three driver mutant genes (KRAS/TP53/SMAD4) with ISET-enriched CTC of PDAC patients.

Key Points: 
  • A peer-reviewed article, published in the journal Cancer Letters ( click to access article ), describes a Johns Hopkins Medicine study that validated PDAC CTC detection by a targeted scNGS method of three driver mutant genes (KRAS/TP53/SMAD4) with ISET-enriched CTC of PDAC patients.
  • Blood samples from patients with late-stage and metastatic PDAC, showed CTCs with SNVs of KRAS/TP53/SMAD4 and the positive confirmation of immuno-fluorescent staining with Pan-CK/Vimentin/CD45.
  • The validation of this innovative and affordable targeted digital scNGS analysis of mutated PDAC CTC enriched with ISET technology provides the scientific community with a reliable PDAC CTC detection workflow.
  • Although larger cohort studies are needed, this is an opening to a personalized medicine approach in pancreatic cancer patients targeting on CTCs."

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis' Liquid Biopsy Platform in Early Stage Breast Cancer and The Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients

Retrieved on: 
Thursday, March 25, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Anatomical pathology, Circulating tumor cell, Biopsy, Metástasis, Liquid biopsy, Breast cancer

The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.

Key Points: 
  • The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.
  • Moreover, for the first time, it was possible to identify CTC clusters in 5 out of 28 patients with early breast cancer, so far only described in metastatic settings.
  • Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer.
  • The company's proprietary nanocoated slides combined with the automated pre-analytical instrument allow to identify and characterize rare cells in blood, like circulating tumor cells, with unprecedented sensitivity, also in early stage settings.

Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis' Liquid Biopsy Platform in Early Stage Breast Cancer and The Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients

Retrieved on: 
Thursday, March 25, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Anatomical pathology, Circulating tumor cell, Biopsy, Metástasis, Liquid biopsy, Breast cancer

The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.

Key Points: 
  • The full paper can be accessed at https://www.nature.com/articles/s41416-021-01327-8.
  • Moreover, for the first time, it was possible to identify CTC clusters in 5 out of 28 patients with early breast cancer, so far only described in metastatic settings.
  • Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer.
  • The company's proprietary nanocoated slides combined with the automated pre-analytical instrument allow to identify and characterize rare cells in blood, like circulating tumor cells, with unprecedented sensitivity, also in early stage settings.

DGAP-News: Lindis Blood Care Initiates Multicenter Clinical EU Certification Study REMOVE with CATUVAB(R) to Eliminate Tumor Cells from Surgical Blood

Retrieved on: 
Thursday, March 18, 2021
Medical specialties, Clinical medicine, Immunology, Trifunctional antibody, Medicine, Pediatric cancers, Immune system, Circulating tumor cell, Wilms' tumor

With the removal of these tumor cells, it should be possible to safely return the patient's own blood to them during the surgery.

Key Points: 
  • With the removal of these tumor cells, it should be possible to safely return the patient's own blood to them during the surgery.
  • Otherwise, the risk of metastasis from tumor cells being released into the blood during the procedure is assessed as too high.
  • Lindis Blood Care's approach has provided proof-of-concept both in vitro and in an initial clinical study with 15 patients.
  • It consists of a trifunctional antibody and filter that enables tumor cells to be removed reliably from surgical blood using the standard MAT procedure.

Vortex Biosciences Announces Publication in Prenatal Diagnosis journal using its technology for enrichment of circulating trophoblasts from maternal blood liquid biopsy

Retrieved on: 
Monday, March 8, 2021
Branches of biology, Embryology, Midwifery, Biology, Fertility, Zoology, Anatomical pathology, Circulating tumor cell, Oncology, Prenatal testing, Prenatal development, Trophoblast

PLEASANTON, Calif., March 8, 2021 /PRNewswire-PRWeb/ -- Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of "Enrichment of circulating trophoblasts from maternal blood using laminar microscale vortices" in Prenatal Diagnosis on January 12, 2021.

Key Points: 
  • PLEASANTON, Calif., March 8, 2021 /PRNewswire-PRWeb/ -- Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of "Enrichment of circulating trophoblasts from maternal blood using laminar microscale vortices" in Prenatal Diagnosis on January 12, 2021.
  • The peer-reviewed publication describes the use of the Vortex technology to enrich circulating trophoblasts (CTs) from a single tube of maternal blood at week 11-13 of gestation.
  • Using a Y-chromosome specific qPCR assay, between 2 and 6 CTs were detected from 8 mL of maternal blood.
  • Going after the elusive fetal cells in maternal blood is a logical next step and a current focus.